Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE:BMY) has exercised its option for an exclusive worldwide license to a cell therapy candidate utilizing Obsidian Therapeutics' cytoDRiVE™ technology, which aims to control the expression of CD40L, an immunomodulatory factor. This marks the first opt-in decision from Bristol Myers since their collaboration began in January 2019. Obsidian stands to receive potential milestone and royalty payments as part of this agreement, signaling validation of its innovative platform and the advancement of its pipeline programs in cancer therapies.
Vidence, LLC, launched on June 18, 2020, aims to enhance cancer treatment through its SCIMON platform, which integrates clinical and genomic data. This oncology informatics company helps researchers and healthcare providers accelerate cancer treatment innovations. Notably, Vidence collaborates with Bristol Myers Squibb (NYSE: BMY) to analyze treatment patterns and outcomes from a large dataset of over 100,000 patients. The collaboration seeks to improve patient care and outcomes in oncology by utilizing a comprehensive knowledge base.